Jean–Jacques Garaud

Author

Jean–Jacques Garaud

Also Known As

Garaud, Jean-Jacques, J J Garaud, J. J. GARAUD, J. J. Garaud, J.-J. Garaud, J.J. Garaud, Jean-Jacques Garaud, Jean‐Jacques Garaud, Jean–Jacques Garaud

Publications

1.7K

Citations

H-Index

Concepts

All Affiliations

Inserm Hôpital Bichat-Claude-Bernard Université Claude Bernard Lyon 1 Centre Hospitalier Régional et Universitaire de Nancy Ziekenhuis Oost-Limburg

About

Jean–Jacques Garaud is an author at Inserm specializing in medicine, sepsis, and antibiotics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	11	11	1.4K
2	Health Sciences	2	2	71
3	Critical Care Medicine	1	1	44
4	Emergency Medicine	1	1	64
5	Hepatology	1	1	977

Jean–Jacques Garaud

Publications

1.6K

Citations

H-Index

Page 1

	Year	Citations
Adherence to combination therapy enhances sustained response in genotype-1–infected patients with chronic hepatitis C John G. McHutchison, Michael P. Manns, Keyur Patel, Gastroenterology HepatologyHepatitis CGenotype-1–infected PatientsViral HepatitisCombination Therapy Enhances	2002	977
A multicentre open clinical trial of teicoplanin in infections caused by Gram-positive bacteria Philip Starkey Lewis, Jean–Jacques Garaud, Francesca Parenti Journal of Antimicrobial Chemotherapy	1988	77
Evaluation of teicoplanin for treatment of endocarditis caused by gram-positive cocci in 20 patients C. Leport, Christian Perronne, Patrice Massip, Antimicrobial Agents and Chemotherapy August 1987Antimicrobial SusceptibilityAntibioticsGram-positive CocciSide Effects	1989	77
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial Bruno François, Xavier Wittebole, Ricard Ferrer, Intensive Care Medicine Acute CareNeurologic Intensive CareSepsisSepsis PhenotypingPhase 2A	2020	64
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial Bruno François, Simon Lambden, Tom Fivez, The Lancet Respiratory Medicine Phase 2BClinical TrialsProspective EvaluationSepsisTherapeutic Efficacy	2023	60
Renal disposition of gentamicin, dibekacin, tobramycin, netilmicin, and amikacin in humans A Contrepois, N Brion, Jean–Jacques Garaud, Antimicrobial Agents and Chemotherapy Antimicrobial ChemotherapyPharmacokineticsDrug ResistanceRenal FunctionChronic Kidney Disease	1985	52
Vancomycin pharmacokinetics in critically ill patients Jean–Jacques Garaud, B. Régnier, F. Inglebert, Journal of Antimicrobial Chemotherapy Therapeutic Drug MonitoringCritical Care MedicineRenal FunctionSevere SepsisAntibiotics	1984	44
A first‐in‐man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM‐1 receptor inhibition Valérie Cuvier, Ulrike Lorch, Stephan Witte, British Journal of Clinical Pharmacology	2018	40
Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for Gram-positive infections in intensive care patients P Charbonneau, Ian Harding, Jean–Jacques Garaud, Intensive Care Medicine Gram-positive InfectionsAntimicrobial StewardshipAntibioticsMedicineSepsis	1994	28
Determination of vancomycin in serum and tissues by column liquid chromatography using solid-phase extraction J Bauchet, Eric Pussard, Jean–Jacques Garaud Journal of Chromatography B Biomedical Sciences and Applications Gas ChromatographyMedicineBioanalysisAnalytical ChemistrySolid-phase Extraction	1987	26

Page 1